Trial Profile

First-in-human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Healthy and Alzheimer's Diseased Brain

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RP-115 (Primary)
Indications Alzheimer's disease; Dementia
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

25 Jun 2024 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
25 Jun 2024 Planned primary completion date changed from 2 Nov 2024 to 1 Apr 2025.
14 Sep 2023 This study is now an Phase 1/2 study, Planned number of patients changed from 68 to 102, Number of treatment arms has been changed to 4, Patients with Frontotemporal-dementia are now being included in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com